Bromfenac ophthalmic solution is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

• Eye inflammation

Post operative eye inflammation

To treat postoperative inflammation in patients who have had cataract extraction, one drop of Bromfenac ophthalmic solution should be applied to the affected eye(s) twice daily beginning 24 hours after cataract surgery and continuing for the first two weeks.

The most commonly reported adverse experiences reported following use of Bromfenac after cataract surgery include:

• abnormal sensation in eye
• conjunctival hyperemia
• eye irritation (including burning/stinging)
• eye pain
• eye pruritus
• eye redness
• headache
• iritis

Ocular burning/ Eye burning

Eye edema

Headache

• Contains sodium sulfite, a sulfite that, in susceptible individuals, can cause allergic-type reactions such as anaphylactic symptoms and life-threatening or less severe asthmatic episodes. The prevalence of sulfite sensitivity in the general population is unknown, but it is most likely low. Sulfite sensitivity is more common in asthmatics than in nonasthmatics.
• Cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs is possible. As a result, individuals who have previously demonstrated sensitivities to these drugs should be treated with caution.
• Some NSAIDs have the potential to prolong bleeding time by interfering with platelet aggregation. In conjunction with ocular surgery, ocularly applied NSAIDs have been linked to increased bleeding of ocular tissues (including hyphemas).
• All topical nonsteroidal anti-inflammatory drugs (NSAIDs) have the potential to slow or prevent healing. Topical corticosteroids have also been shown to slow or postpone healing. Concurrent use of topical NSAIDs and topical steroids may increase the likelihood of healing issues.
• Keratitis may result from the use of topical NSAIDs. Continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation in some susceptible patients.
• Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events that can be sight threatening. In these patients, topical NSAIDs should be used with caution.